Urinalysis Market worth $7.16 billion by 2031 - Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla. , Aug. 24, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Urinalysis Market is projected to reach USD 7.16 billion by 2031 from USD 4.88 billion in 2026, at a CAGR of 8.0% during the forecast period.

Browse 490 market data Tables and 50 Figures spread through 430 Pages and in-depth TOC on 'Urinalysis Market- Global Forecast to 2031'

Urinalysis Market Size & Forecast:

• Market Size Available for Years: 2026–2031
• 2026 Market Size: USD 4.88 billion
• 2031 Projected Market Size: USD 7.16 billion
• CAGR (2026–2031): 8.0%

Urinalysis Market Trends & Insights:

• Asia Pacific is expected to register the fastest growth in the urinalysis market during the forecast period.
• By product, the consumables segment accounted for the largest market share of 72.5% in 2025.
• By test type, the pregnancy & fertility tests segment accounted for the largest market share of 42.8% in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153479294

The urinalysis market is growing, driven by several factors, including the rising prevalence of urinary tract infections (UTIs), diabetes, and kidney and liver diseases, as well as the growing geriatric population and associated age-related disorders. The growing need for early disease detection, routine health screening, and disease monitoring is increasing demand for urinalysis testing across hospitals, diagnostic laboratories, and home care settings. In addition, the increasing adoption of point-of-care (PoC) testing and rising healthcare expenditure, particularly in emerging markets, are driving demand for advanced urinalysis analyzers, test strips, reagents, and other diagnostic products.

Technological advancements, such as automated urine analyzers, digital microscopy, flow cytometry, and advanced biochemical testing, have significantly improved the speed, accuracy, and efficiency of urinalysis.

A major development transforming the urinalysis market is the growing adoption of automated and integrated urine analysis systems. These systems streamline sample processing, reduce manual intervention, improve workflow management, and enable rapid urine analysis. Automation minimizes operator-related errors, enhances testing consistency, and increases laboratory throughput, making these technologies highly suitable for hospitals, diagnostic laboratories, and other healthcare settings handling large testing volumes. As advanced automated urinalysis systems become more accessible and widely adopted, they are expected to support faster, more reliable, and standardized urine testing across various healthcare settings.

By product, the consumables segment held the largest share in the urinalysis market in 2025.

By product, the urinalysis market is segmented into consumables and instruments. The consumables segment held the largest market share in 2025, primarily due to their recurring use and frequent replacement needs. Products such as pregnancy and fertility kits, dipsticks, reagents, and disposables are required for routine urinalysis testing, resulting in continuous demand across hospitals, diagnostic laboratories, clinics, and home care settings. The wide availability of consumables for different testing requirements and the growing volume of urine-based diagnostic tests further support the segment's leading position.

In 2025, the pregnancy & fertility tests segment held the largest share in the urinalysis market.

By test type, the urinalysis market is segmented into biochemical tests, sediment urinalysis, and pregnancy & fertility tests. The pregnancy & fertility tests segment accounted for the largest market share in 2025, supported by growing awareness of reproductive health and family planning, particularly in developing countries. Technological advancements have improved the accuracy, ease of use, and speed of these tests, while the availability of convenient home-based testing and rapid results has further increased their adoption. Ongoing product innovation and R&D investments by key market players are also contributing to the expansion of this segment.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=153479294

North America is the largest regional market for urinalysis.

The urinalysis market is segmented into five key regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share of the urinalysis market. The region's well-established healthcare infrastructure, advanced diagnostic facilities, and skilled healthcare workforce support the widespread integration of urinalysis into routine clinical practice. The high adoption of advanced diagnostic technologies, including automated urine analyzers and other sophisticated urinalysis systems, further contributes to market growth. In addition, the high prevalence of chronic conditions such as diabetes, kidney diseases, and urinary tract infections increases the need for regular urine testing for disease screening, diagnosis, and monitoring, supporting the region's leading market position.

Key Players

Leading players in the Urinalysis companies include Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Cardinal Health (US), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Abbott (US), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (Japan), and Waters Corporation (US), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=153479294

Urinalysis Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The urinalysis market has seen sustained strategic investment, product launches, and technology development, driven by rising testing volumes, growing demand for automation, and the need for faster, standardized urine testing. Key developments include Siemens Healthineers AG's December 2023 launch of the Atellica UAS 60 Analyzer, a compact instrument for automated urine sediment analysis that expands the company's urinalysis portfolio with a space-efficient, high-throughput solution. More recently, Danaher Corporation launched the DxU 1800 System in July 2026, a fully automated urinalysis solution that combines a new urine chemistry analyzer and consumables with microscopy technology. The system is designed to standardize urine testing, increase throughput, reduce manual intervention, and help laboratories manage rising diagnostic volumes. These developments underscore the industry's growing focus on automation, integrated workflows, and technologies that improve laboratory efficiency and clinical decision-making.

Revenue Shift Context

The urinalysis market is shifting toward automated, integrated, and high-throughput diagnostic workflows, supported by rising demand for advanced urine analyzers, high-volume consumables, and technologies that improve laboratory efficiency. The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a CAGR of 8.0%. While instruments, including automated and integrated urine analyzers, represent significant capital investments, consumables account for a larger share of market revenue, driven by the recurring need for dipsticks, reagents, pregnancy and fertility kits, and other disposables used in routine urine testing.

Mergers and Acquisitions

Mergers and acquisitions in the urinalysis market are increasingly focused on expanding capabilities in automated urine testing, rapid diagnostics, digital microscopy, biochemical analysis, and integrated urinalysis workflows.  Companies are pursuing acquisitions and strategic partnerships to broaden their product portfolios, enhance automation, improve testing efficiency, and strengthen their presence across clinical laboratories, hospitals, and point-of-care settings.

URINALYSIS MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023–JULY 2026

Company Revenue Share Details

The top five players in the global urinalysis market accounted for approximately 52.0% of total market revenue in 2025, indicating a moderately consolidated competitive landscape. Siemens Healthineers AG and F. Hoffmann-La Roche Ltd. dominate the market, supported by their broad urinalysis product portfolios, established global presence, and strong distribution networks. The top 10 companies collectively accounted for approximately 72–78% of global market revenue, including Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Cardinal Health, Sysmex Corporation, Thermo Fisher Scientific, Inc., Danaher Corporation, Abbott, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, and Waters Corporation. The remaining market is distributed among regional manufacturers, specialized diagnostic companies, and other healthcare providers. Continued adoption of automated urinalysis systems, expansion of diagnostic testing volumes, technological advancements, and strategic partnerships are expected to influence company revenue shares during the forecast period.

Browse Adjacent Market: Medical Devices Market Research Reports &Consulting

See More Latest Medical Devices Reports:

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031

In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/urinalysis-systems-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/urinalysis-systems.asp